3.59 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||3.52 x 1100|
|Ask||3.59 x 1100|
|Day's Range||3.43 - 3.63|
|52 Week Range||1.74 - 6.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
July 17 (Reuters) - Geron Co Ltd: * SAYS UNIT TO INVEST 283.0 MILLION YUAN ($42.35 million) IN STAINLESS STEEL PLATE PROJECT Source text in Chinese: https://bit.ly/2uGwvZt Further company coverage: ($1 ...
HENDERSON, NV / ACCESSWIRE / July 8, 2018 / In order to take a drug to market the cost was estimated to be $2.4 billion. This has caused many biotech firms to enter the device market, rather than drug ...
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...
IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent. Its primary efficacy endpoint is planned to be the rate of RBC-TI (red blood cell transfusion independence) for at least eight weeks. Key secondary endpoints are to be RBC-TI rates for 24 weeks, the amount of and changes in red blood cell transfusions, and hematologic improvement.
Its interest expenses fell YoY (year-over-year) to $18,000 from $21,000, and its net loss was stable YoY, growing slightly to ~$7.19 million from $7.18 million. Its net loss per share improved YoY, shrinking to $0.04 from $0.05. In Q1 2018, Geron’s cash outflow from operating activities rose YoY to $7.37 million from $7.31 million. Its current ratio, which measures how effectively it can meet its short-term obligations, improved YoY to 20.8 from 9.
In August 2015, Geron (GERN) entered into a market issuance sales agreement with MLV, under which Geron could issue and sell its common stock for up to $50 million. Under the agreement, in Q1 2018, Geron sold ~776,800 shares of its common stock for net proceeds of ~$1.6 million. Geron entered into a collaboration and licensing agreement with Janssen Biotech in November 2014.
IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor. The primary endpoints for the trial are the spleen and symptom response rates. The secondary endpoints of the trial include safety and overall survival. Geron expects an overall survival assessment to provide key information for the imetelstat program for potential future clinical trials. The drug’s safety profile was found to be consistent with prior clinical trials focusing on hematologic malignancies.
In collaboration with Janssen Biotech, biopharmaceutical company Geron (GERN) is currently supporting the clinical development of imetelstat for hematologic myeloid malignancies. Early clinical data for the drug suggests it may have disease-modifying activity by inhibiting progenitor cells of malignant clones for myelofibrosis, myelodysplastic syndromes, and essential thrombocythemia. The sole analyst covering Geron recommends “hold.” In April, there were three analysts covering the stock, of which one recommended “buy,” and two recommended “hold.” Their target price was $5.50.
In Q1 2018, Geron’s (GERN) license fee and royalty revenue fell YoY (year-over-year) to $318,000 from $537,000, with license fee revenue falling YoY to $248,000 from $409,000. This decrease was due to a reduction in its number of active agreements for research licenses related to its human telomerase reverse transcriptase technology.
NEW YORK, NY / ACCESSWIRE / June 18, 2018 / Biotech stocks Geron Corporation and BioMarin Pharmaceutical were both rising in Friday’s trading session with gains of almost 10% by the close of the day. While Geron had no significant news, BioMarin announced last week that it has dosed its first participant in a global phase II study for vosoritide, an experimental drug for the treatment of achondroplasia.
Geron Corporation (GERN) today announced the oral presentation of updated data from the ongoing original Part 1 of IMerge, the Phase 2/3 trial of imetelstat in lower risk myelodysplastic syndromes (MDS). The data was presented by Dr. David Steensma from the Dana-Farber Cancer Institute at the 23rd Congress of the European Hematology Association (EHA) held in Stockholm, Sweden on June 17. Imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, Inc. (Janssen) on a worldwide basis.
On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC).
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / U.S. markets finished higher and logged strongest week in months as investors shrug off tensions between U.S. and its allies. The Dow Jones Industrial Average ...
Why an airplane giant, a drugmaker, and an alcoholic beverage specialist could each see more market-thumping gains ahead.
NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...
Geron Corporation (GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been selected for an oral presentation at the 23rd Congress of the European Hematology Association (EHA) to be held in Stockholm, Sweden from June 14-17, 2018. The abstract contains updated data (as of January 2018) from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS) being conducted by Janssen Research & Development, LLC.